高危因素联合分层法在预测N2-3M0期鼻咽癌预后的临床价值分析

doi:10.3760/cma.j.issn.1004-4221.2019.12.002

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的分析高危因素联合分层法在预测N2-3M0期鼻咽癌预后的临床价值。方法 2013-2015年间226例N2-3M0期首程鼻咽癌病例被纳入研究,分析肿瘤体积、颈部转移淋巴结特征(坏死、融合)和T、N分期等与生存的关系,分析影响生存的高危因素,探讨高危因素联合分层法在预测预后的价值。结果 N3期、Vn≥47.15cm³和淋巴结融合是N2-3M0期鼻咽癌患者远处转移的高危因素,根据高危因素分为低危、中危、高危、极高危组。生存分析显示低危、中危、高危、极高危组3年总生存率分别为84.2%、76.7%、58.7%、36.4%(P<0.001),无远处转移生存率分别为87.3%、85.2%、54.5%、12.1%(P<0.001),无进展生存率分别为76.8%、74.3%、49.2%、12.1%(P<0.001),无局部区域复发生存率分别为89.2%、88.5%、91.5%、88.3%(P=0.914)。比较N分期、Vn分组、淋巴结融合分组和高危因素联合分层法的无远处转移生存曲线发现:高危因素联合分层法将组间曲线分离的更开,明显优于其他三组(P<0.05)。结论高危因素联合分层法在预测N2-3M0期鼻咽癌患者预后的临床价值更高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈俊妮
	袁波
	杨时平
	陈佳玮
	林香英
	李昭君
	陈峰
	王振平
	王奋
	王一鸣

关键词 ：鼻咽肿瘤, 高危因素联合分层法, 临床价值

Abstract：Objective To evaluate the clinical value of high-risk factors in combination with stratification method in predicting the clinical prognosis of patients diagnosed with N2-3M0 nasopharyngeal carcinoma (NPC). Methods A total of 226 N2-3M0 NPC patients who underwent IMRT from November 2013 to May 2015 were enrolled in this study. The relationship between tumor volume, cervical metastatic lymph node characteristics (necrosis and fusion) and T and N staging was analyzed. The high-risk factors that affected the survival were identified. The value of high-risk factors combined with stratification method in predicting the clinical prognosis was assessed. Results N3 staging, Vn≥47.15cm³ and lymph node fusion (LNF) were the high-risk factors for distant metastasis in patients with stage N2-3M0 NPC. All patients were classified into the low-risk, medium-risk, high-risk and extremely high-risk groups according to high-risk factors. For patients in the low-risk, medium-risk, high-risk and extremely high-risk groups, the 3-year overall survival rates were 84.2%,76.7%,58.7% and 36.4%(all P<0.001), 87.3%,85.2%,54.5% and 12.1% for the distant metastasis-free survival (DMFS) rates (all P<0.001), 76.8%,74.3%,49.2% and 12.1%for the progression-free survival (PFS) rates (all P<0.001), and 89.2%,88.5%,91.5% and 88.3% for the loco-regional recurrence-free survival (LRRFS) rates (P=0.914), respectively. The risk stratification method showed the best curve separation for DMFS compared to the Vn, N staging and LNF classification groups (all P<0.05). Conclusion High-risk factors in combination with stratification method has the highest clinical value in predicting the clinical prognosis of N2-3M0 NPC patients.

Key words： Nasopharyngeal neoplasm High-risk factors combined with stratification method Clinical value

收稿日期: 2019-05-08

基金资助:海南省自然科学基金项目(817304)

引用本文:

陈俊妮,袁波,杨时平等. 高危因素联合分层法在预测N2-3M0期鼻咽癌预后的临床价值分析[J]. 中华放射肿瘤学杂志, 2019, 28(12): 885-889.

Chen Junni,Yuan Bo,Yang Shiping et al. Analysis of clinical value of high-risk factors combined with stratification analysis in predicting clinical prognosis of N2-3M0 nasopharyngeal carcinoma patients[J]. Chinese Journal of Radiation Oncology, 2019, 28(12): 885-889.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2019.12.002 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2019/V28/I12/885

[1]Zhang MX,Li J,Shen GP,et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy:a 10-year experience with a large cohort and long follow-up[J]. Eur J Cancer,2015,51(17):2587-2595. DOI:10.1016/j.ejca.2015.08.006.
[2]Ng WT,Lee MC,Hung WM,et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys,2011,79(2):420-428. DOI:10.1016/j.ijrobp.2009.11.024.
[3]孙学明,黄莹,陈春燕,等.N晚期鼻咽癌调强放疗远期疗效评价[J]. 中华放射肿瘤学杂志,2013,22(3):225-229. DOI:10.3760/cma.j.issn.1004-4221.2013.03.014.
Sun XM,Huang Y,Chen CY,et al. Evaluation of the long-term efficacy of advanced nasopharyngeal cancer in N[J]. Cin J Radait Oncol,2013,22(3):225-229.DOI:DOI:10.3760/cma.j.issn.1004-4221.2013.03.014.
[4]Amin MB,Edge S,Greene F,et al. AJCC cancer staging manual[M].8th ed. New York:Springer,2017.
[5]Sun Y,Li WF,Chen NY,et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase 3,multicentre,randomised controlled trial[J]. Lancet Oncol,2016,17(11):1509-1520. DOI:10.1016/S1470-2045(16)30410-7.
[6]Peng H,Chen L,Zhang J,et al. Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma:a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy[J]. J Cancer,2017,8(3):371-377. DOI:10.7150/jca.16732.
[7]魏嘉旺,黄蓉,余昕,等.3~4周期NACT对N2-N3期鼻咽癌临床价值分析[J]. 中华放射肿瘤学杂志,2017,26(4):380-383. DOI:10.3760/cma.j.issn.1004-4221.2017.04.003.
Wei JW,Huang R,Yu X,et al. 3-4 cycle NACT analysis N2-N3 nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2017,26(4):380-383. DOI:10.3760/cma.j.issn.1004-4221.2017.04.003.
[8]侯雪,张力,赵充,等. 血浆EB病毒DNA浓度预测鼻咽癌远处转移的研究[J]. 癌症,2006,25(7):785-792. DOI:10.3969/j.issn.1000-467X.2006.07.001.
Hou X,Zhang L,Zhao C,et al. Study on the prediction of distant metastasis of nasopharyngeal cancer in plasma EB virus DNA concentration[J]. Chin J Cancer, 2006,25(7):785-792. DOI:10.3969/j.issn.1000-467X.2006.07.001.
[9]Peng L,Yang Y,Guo R,et al. Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma:an updated interpretation[J]. Cancer Med,2018,7(12):5988-5998. DOI:10.1002/cam4.1858.
[10]Fung SY,Lam JW,Chan KC. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma[J]. Chin Oncol,2016,5(2):18. DOI:10.21037/cco.2016.03.07.
[11]Chen QY,Guo SY,Tang LQ,et al. Combination of tumor volume and Epstein-Barr virus DNA improved prognostic stratification of stage Ⅱ nasopharyngeal carcinoma in the IMRT Era:a large-scale cohort study[J]. Cancer Res Treat,2017,50(3):861-871. DOI:10.4143/crt.2017.237.
[12]Lu L,Li J,Zhao C,et al. Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Oral Oncol,2016,60(1):18-24. DOI:10.1016/j.oraloncology.2016.06.013.
[13]Zhou X,Ou X,Yang Y,et al. Quantitative metastatic lymph node regions on magnetic resonance imaging are superior to AJCC N classification for the prognosis of nasopharyngeal carcinoma[J]. J Oncol,2018,2018:9172585. DOI:10.1155/2018/9172585.
[14]Lan M,Huang Y,Chen CY,et al. Prognostic value of cervical nodal necrosis in positive cervical nodal metastasis at MRI maging[J]. Radiology,2015,276(2):619. DOI:10.1148/radiol.15154020.
[15]Feng Y,Cao C,Hu Q,et al. Prognostic value and staging classification of lymph nodal necrosis in nasopharyngeal carcinoma after intensity modulated radiotherapy[J].2019,51(3):1222-1230. DOI:10.4143/crt.2018.595.
[16]Zhang LL,Li JX,Zhou GQ,et al. Influence of cervical node necrosis of different grades on the prognosis of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J]. J Cancer,2017,8(6):959-966. DOI:10.7150/jca.17998.
[17]Zhang LL,Zhou GQ,Li YY,et al. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy:a large-scale retrospective study[J]. Cancer Med,2017,6(12):2822-2831. DOI:10.1002/cam4.1233.
[18]Zhou X,Yang YQ,Ou XM,et al. Interplay of tumor spread,volume and Epstein-barr virus DNA in nasopharyngeal carcinoma:feasibility of an integrative risk stratification scheme[J]. J Cancer,2018,9(22):4271-4278. DOI:10.7150/jca.26777.